NEW YORK (Reuters Health)—A Dutch study confirms that reduced serum levels of insulin-like growth factor-1 (IGF-1) are associated with increased fracture risk in elderly women, but not men. In an Aug. 31 online paper in the Journal of Clinical Endocrinology & Metabolism, Dr. N.C. van Varsseveld, of VU University Medical Center, Amsterdam, and colleagues noted that…
Search results for: fracture
Growth Hormone Reduces Fractures in Women with Osteoporosis
NEW YORK (Reuters Health)—Growth hormone is associated with a decrease in fractures in women with postmenopausal osteoporosis even a decade after treatment ceases, researchers from Sweden report. “We were surprised and pleased to find that the patients had a reduced risk of fracture so many years after the growth hormone treatment was ceased,” Dr. Emily…
Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
In a 25 month Phase 3 trial, abaloparatide-SC reduced the risk of new fractures in patients suffering from postmenopausal osteoporosis. Plus, the FDA launches a new drug safety website.
2014 ACR/ARHP Annual Meeting: Bone Fracture Concerns in Children
Recognizing, reducing risk of bone fractures in pediatric patients with rheumatic disease, taking glucocorticoid therapy
Atypical Fractures Associated with Bisphosphonates
Plus, FX006, odanacatib and other rheumatology drug news, safety updates
New Treatments Needed to Prevent Fractures in Osteoporosis
Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact
Unexpected Benefits of Bisphosphonates after Hip Fracture
Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.
Glucocorticoids a Fracture Risk at Any Dose
Updated recommendations advocate doing more to determine fracture risk and the need for preventive therapy
Concrete Relief for Vertebral Fractures
PVA reduces fracture pain—but is it overused?
Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. With thousands of research abstracts presented at the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 43
- Next Page »